Americans are increasingly turning to bitcoin to purchase peptides—drugs marketed for weight loss, muscle gain, and life extension. According to my data, based on blockchain transaction analysis, sellers of such substances received about $32 million in cryptocurrency in the first quarter of 2026. This is a staggering 700% increase compared to the same period last year.

Approved peptides that have undergone clinical trials are sold in legal pharmacy chains like Walgreens and CVS. However, a significant portion of online trade goes underground. Cheap analogs are shipped from foreign labs without a prescription or insurance, and the packaging often bears the label "not for human use."

Why cryptocurrency has become the primary means of payment

Banks and payment systems refuse to service such sellers due to high compliance risks. As a result, some suppliers accept payment exclusively in bitcoin. Notably, for many buyers, this becomes their first experience with cryptocurrencies. For example, a 49-year-old marketing director from the U.S. named Zach, trying to buy retatrutide (an Eli Lilly drug), found a Chinese supplier. The supplier agreed to ship 20 vials for $240—three times cheaper than on the U.S. market. But the seller only accepted digital assets, and Zach had to buy bitcoin for the first time.

Three stages of explosive growth

Analysis of on-chain data reveals three key stages. Before 2025, it was a niche "underground" market with an inflow of about $200,000 per month. Then the topic came to the attention of the Make America Healthy Again movement, coinciding with the appointment of Robert F. Kennedy Jr. as head of the U.S. Department of Health and Human Services. A direct causal link is hard to establish, but the trend is clear.

A sharp surge occurred at the end of 2025, when peptides went viral in the TikTok subculture of looksmaxxing, obsessed with improving appearance. The average monthly inflow quadrupled to $9.9 million, and in peak months exceeded $10 million.

Former Coinbase Global employee Sarah Graham estimated the annual turnover of the peptide market at $100 million as early as 2023. According to TRM Labs, in 2025, digital asset inflows into this sector reached $41.4 million—a 20% increase year-over-year. TRM Labs' global director of policy, Ari Redbord, compares this dynamic to the early stages of shadow online markets like Silk Road.

Major players are moving to stablecoins

The market is highly uneven. The bulk of the volume comes from a narrow group of large sellers. Small players experiment with different coins, but large suppliers almost exclusively use bitcoin and stablecoins. Among sellers with an average deposit of $1,000 or more, "stablecoins" dominate—this way they hedge against volatility in large and cross-border purchases.

China is the main supplier of raw materials

The primary raw materials for peptides are produced in China. Chinese chemical manufacturers are actively expanding their presence in this niche. Over three quarters of 2025, imports from China to the U.S. roughly doubled to over $300 million. Some suppliers have come from the drug trade: for example, the company Bigreat Technology, which previously supplied fentanyl precursors, now sells cosmetic peptides through its subsidiary Zhengzhou DEPU Technology.

My analysis: This market demonstrates a classic shadow economy model, where cryptocurrency becomes an ideal tool for bypassing traditional financial barriers. A 700% growth in a year is not just an anomaly but a signal that regulators and payment systems will have to adapt to new realities. Peptides are just the tip of the iceberg; similar schemes could spread to other categories of goods and services.